Yasmin Nabil

Abstract Renal cell carcinomas (RCC) comprise multiple molecularly distinct cancers but most are treated empirically with therapies designed for clear cell RCC (ccRCC), the most common subtype, due to incomplete understanding of subtype-specific biology. We analyzed single-cell transcriptomes and chromatin accessibility profiles from translocation renal cell carcinoma (tRCC), an aggressive RCC defined by oncogenic TFE3 gene fusions.

Human clear cell renal cell carcinoma cell line skrc-59 (obtained from Dr. Gerd Ritter, Memorial Sloan-Kettering Cancer Center, New York, USA) was engineered to express high levels of human CAIX (skrc-59 CAIX+) [21] and mCardinal fluorescent protein. Using CRISPR Cas9, sgCAIX skrc-59 cell line was engineered to knock out CAIX. MMNK-1 cholangiocyte cell line [22] was purchased from Japanese Collection of Research Biosources Cell Bank (JCRB).